Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - escitalopram oxalate, quantity: 12.774 mg - tablet, film coated - excipient ingredients: maize starch; microcrystalline cellulose; croscarmellose sodium; magnesium stearate; mannitol; titanium dioxide; hypromellose; macrogol 6000 - treatment of major depression. ,treatment of social anxiety disorder (social phobia). ,treatment of generalised anxiety disorder. ,treatment of obsessive-compulsive disorder.

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - glatiramer acetate, quantity: 20 mg/ml - injection, solution - excipient ingredients: mannitol; water for injections - reduction of the frequency of relapses in patients with relapsing remitting multiple sclerosis.,treatment of patients with a single clinical event suggestive of multiple sclerosis and at least two clinically silent mri lesions characteristic of multiple sclerosis, if alternative diagnoses have been excluded.

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - glatiramer acetate, quantity: 40 mg/ml - injection, solution - excipient ingredients: mannitol; water for injections - reduction of the frequency of relapses in patients with relapsing remitting multiple sclerosis.,treatment of patients with a single clinical event suggestive of multiple sclerosis and at least two clinically silent mri lesions characteristic of multiple sclerosis, if alternative diagnoses have been excluded.

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - estradiol hemihydrate, quantity: 10.3 microgram (equivalent: estradiol, qty 10 microgram) - pessary, modified release - excipient ingredients: hypromellose; lactose monohydrate; magnesium stearate; maize starch; macrogol 6000 - estro-pess is indicated for the treatment of atrophic vaginitis due to estrogen deficiency in postmenopausal women.,estro-pess is not intended for children or males.

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

theramex australia pty ltd - estradiol hemihydrate, quantity: 1 mg; progesterone, quantity: 100 mg - capsule, soft - excipient ingredients: mono- and di- glycerides; gelatin; glycerol; purified water; lauroyl macrogolglycerides; hydrolysed gelatin; allura red ac; titanium dioxide; propylene glycol; ethyl acetate; ethanol; isopropyl alcohol; strong ammonia solution; polyvinyl acetate phthalate; macrogol 400 - bijuva 1/100 is indicated for use during continuous combined hormone replacement therapy (hrt) for estrogen deficiency symptoms in postmenopausal women with an intact uterus and with at least 12 months since last menses.

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - safinamide mesilate, quantity: 65.88 mg (equivalent: safinamide, qty 50 mg) - tablet, film coated - excipient ingredients: crospovidone; magnesium stearate; colloidal anhydrous silica; microcrystalline cellulose; colour; hypromellose; macrogol 6000 - xadago is indicated for the treatment of adult patients with fluctuating idiopathic parkinson?s disease (pd) as add-on therapy to a regimen that includes levodopa (l-dopa)

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - safinamide mesilate, quantity: 131.76 mg (equivalent: safinamide, qty 100 mg) - tablet, film coated - excipient ingredients: colloidal anhydrous silica; magnesium stearate; microcrystalline cellulose; crospovidone; colour; hypromellose; macrogol 6000 - xadago is indicated for the treatment of adult patients with fluctuating idiopathic parkinson?s disease (pd) as add-on therapy to a regimen that includes levodopa (l-dopa)

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - paroxetine hydrochloride, quantity: 22.2 mg - tablet, film coated - excipient ingredients: magnesium stearate; microcrystalline cellulose; mannitol; titanium dioxide; sodium starch glycollate; colloidal anhydrous silica; hypromellose; copovidone; purified talc - paroxetine is indicated for the treatment of : - major depression and for the prevention of relapse of depressive symptoms - obsessive compulsive disorder (ocd) and prevention of relapse of ocd - panic disorder and for the prevention of relapse of panic disorder - social anxiety disorder/social phobia - general anxiety disorder - post-traumatic stress disorder.

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

arico corporation pty ltd -

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

arico corporation pty ltd -